Lonsurf combination tablets T15 (trifluridine, tipiracil) for colorectal and gastric cancer

Are Lonsurf combination tablets T15 (trifluridine, tipiracil) effective for colorectal and gastric cancer?

Package details: 20 tablets

Active components: trifluridine, tipiracil hydrochloride

Lonsurf Combination Tablets T15 for Advanced Colorectal and Gastric Cancer

Lonsurf combination tablets T15 are colorectal cancer tablets used for unresectable advanced or recurrent colorectal cancer that has progressed after chemotherapy. They are also used as a gastric cancer treatment for unresectable advanced or recurrent gastric cancer when the disease has continued to progress after previous chemotherapy.

Each tablet contains two active components: trifluridine and tipiracil hydrochloride. Together, these ingredients are designed to slow tumor growth by acting directly on the DNA process inside cancer cells. For patients and families comparing treatment information before they buy trifluridine, Lonsurf is best understood as an oral anticancer medicine used after earlier treatments are no longer controlling the disease well.

How Lonsurf Works in Tumor Cells

The main anticancer component in Lonsurf is trifluridine. After entering tumor cells, trifluridine is incorporated into the DNA of those cells. DNA is the instruction material that cancer cells need in order to divide, multiply, and continue forming new tumor tissue.

When trifluridine becomes part of tumor-cell DNA, it interferes with normal DNA function. This helps inhibit tumor growth, because the cancer cells can no longer use their genetic material as efficiently for continued multiplication.

Tipiracil hydrochloride has a different but important supporting role. It helps maintain the activity of trifluridine in the body by reducing its breakdown. This allows trifluridine to remain available long enough to reach tumor cells and exert its inhibitory effect on tumor growth. The two components therefore work as a combination rather than as separate, unrelated ingredients.

Why Trifluridine and Tipiracil Are Combined

The combination of trifluridine and tipiracil is important because trifluridine alone is broken down quickly in the body. Tipiracil helps protect trifluridine from rapid degradation, making the treatment more suitable as an oral anticancer medicine.

This combination supports a more sustained exposure to the active anticancer component. As a result, trifluridine/tipiracil tablets can be used in later-line treatment settings, where cancer has already progressed after other chemotherapy regimens.

The treatment approach is especially relevant in:

• unresectable advanced colorectal cancer after chemotherapy
• recurrent colorectal cancer that cannot be removed by surgery
• unresectable advanced gastric cancer after chemotherapy
• recurrent gastric cancer that has progressed despite earlier treatment

Benefits of Lonsurf Combination Tablets T15

Lonsurf offers a treatment option for cancers that have already been treated with chemotherapy but continue to progress. In these situations, the goal is not simply to attack cancer cells in a general way, but to use a mechanism that directly interferes with tumor-cell DNA.

Because trifluridine becomes incorporated into DNA, Lonsurf acts at a fundamental level of tumor-cell growth. This mechanism helps explain why the medicine is used when colorectal or gastric cancer has become difficult to control with previous therapies.

For patients with advanced disease, the main benefits of Lonsurf combination tablets T15 include:

• an oral treatment option for later-line cancer therapy
• direct action on tumor-cell DNA
• inhibition of tumor growth through trifluridine incorporation
• use in both advanced colorectal cancer and advanced gastric cancer after chemotherapy
• a combination formula in which tipiracil helps preserve trifluridine activity

These features make Lonsurf an important option among colorectal cancer tablets for patients whose disease has progressed after standard chemotherapy.

Effectiveness in Advanced Gastric Cancer

Evidence from clinical practice supports the role of trifluridine/tipiracil in heavily pretreated gastric cancer. In the scientific article “Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer,” trifluridine/tipiracil therapy was evaluated in 98 patients with advanced gastric cancer who had already received multiple previous treatments.

The data from this study are relevant because they reflect a difficult treatment stage: patients had advanced gastric cancer and had been heavily pretreated, including prior immunotherapy. In this setting, the study showed that trifluridine/tipiracil therapy could be a therapeutic option after immunotherapy, supporting its practical value in later-line gastric cancer treatment.

The same article also reported that no treatment-related death occurred among the 98 patients. This is an important real-world finding for a medicine used in patients who may already be weakened by advanced disease and previous anticancer treatment. The toxicities were described as manageable even when trifluridine/tipiracil was used as fourth-line or later-line therapy after prior immunotherapy.

Role in Colorectal Cancer Treatment

For unresectable advanced or recurrent colorectal cancer, Lonsurf is used after previous chemotherapy has failed to adequately control the disease. At this stage, cancer cells may have continued to grow despite earlier medicines, and additional treatment options may become limited.

Lonsurf provides a different mechanism through trifluridine incorporation into tumor-cell DNA. Instead of only blocking external growth signals, it interferes with the DNA structure that cancer cells rely on for multiplication. This makes the medicine suitable for later-stage colorectal cancer treatment, especially when the disease is no longer responding as expected to previous chemotherapy.

For people reviewing colorectal cancer tablets, Lonsurf combination tablets T15 stand out because they contain both an active DNA-targeting component and a second component that helps keep that activity available in the body.

Role in Gastric Cancer Treatment After Chemotherapy

Lonsurf is also used for unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy. In advanced gastric cancer, treatment decisions often depend on what has already been used and how the cancer has responded.

When earlier chemotherapy does not continue to control the disease, trifluridine/tipiracil offers another treatment pathway. Its mechanism is not based on surgery or local tumor removal. Instead, it works systemically through the bloodstream, reaching tumor cells and interfering with their DNA-based growth process.

This makes Lonsurf a relevant gastric cancer treatment in later-line care, especially for patients whose cancer has progressed after several previous therapies.

What Makes Lonsurf Combination Tablets T15 Different

Lonsurf combination tablets T15 are not a general supplement or supportive care product. They are anticancer tablets with a defined pharmacological mechanism. The trifluridine component is incorporated into tumor-cell DNA, while tipiracil hydrochloride supports the persistence of trifluridine activity.

This dual-component design helps explain why the medicine is used in serious cancer settings where previous chemotherapy has not provided enough disease control. It also explains why the product is described as trifluridine/tipiracil tablets rather than as trifluridine alone.

Therapeutic effect: treatment of unresectable advanced or recurrent colorectal cancer and unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy

Dosage and administration: For adults, this medicine is taken twice a day, after breakfast and after dinner.

Take it for 5 days in a row, then stop for 2 days. Repeat this schedule one more time. After that, stop taking the medicine for 14 days. This whole schedule is one treatment course.

The usual starting dose of trifluridine depends on your body surface area, or BSA:

• BSA less than 1.07 m²: 35 mg per dose
• BSA 1.07 to less than 1.23 m²: 40 mg per dose
• BSA 1.23 to less than 1.38 m²: 45 mg per dose
• BSA 1.38 to less than 1.53 m²: 50 mg per dose
• BSA 1.53 to less than 1.69 m²: 55 mg per dose
• BSA 1.69 to less than 1.84 m²: 60 mg per dose
• BSA 1.84 to less than 1.99 m²: 65 mg per dose
• BSA 1.99 to less than 2.15 m²: 70 mg per dose
• BSA 2.15 m² or more: 75 mg per dose

The dose may be reduced depending on your condition.

Each tablet of this medicine contains 15 mg of trifluridine. It may be taken together with another tablet that contains the same ingredients in a different strength, such as 20 mg.

Do not take Lonsurf on an empty stomach. Taking it without food can increase the amount of medicine in your blood and may make side effects stronger.

Keep a record of when you take the medicine, how you feel, and any symptoms you notice. Show this record to your doctor or pharmacist at your next visit.

Contraindications and precautions: Store in a dry cool place, out of reach of children. Do not use for pregnant, possibly pregnant or breastfeeding women.

During treatment, patients need regular blood tests to check their blood, liver, and kidney function. These tests help find side effects that may not cause symptoms. Be sure to visit your doctor according to the schedule.

Female patients who may become pregnant, must use reliable contraception while taking this medicine and for 6 months after finishing the treatment. Male patients must use a condom while taking this medicine and for 3 months after stopping it.

Do not expose to sunlight or heat. If allergic symptoms occur, discontinue use.